Alembic gets USFDA nod for Clomipramine HCL Capsules

Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD).

50
USFDA
Picture: Pixabay

Last Updated on August 7, 2021 by The Health Master

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg and 75 mg, the company said in a statement.

It also said that the approved ANDA is therapeutically equivalent to the reference listed drug (RLD) product, Anafranil Capsules, 25 mg, 50 mg and 75 mg, of SpecGX LLC.

Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD).

Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg and 75 mg, have an estimated market size of $32 million for twelve months ending June 2021, according to IQVIA, the statement added.

Alembic has a cumulative total of 149 ANDA approvals (131 final approvals and 18 tentative approvals) from FDA,” it further mentioned.

Zydus Cadila gets final nod from USFDA for Fulvestrant injection

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

Zydus Cadila gets USFDA nod for Ibrutinib tablets

Lupin gets USFDA nod for generic Antifungal drug

Unichem gets tentative USFDA nod for drug to treat Diabetes

7 Tips Every Men Should Follow In Healthy Skincare Regime

Only 0.20% of drug samples declared Adulterated in FY 2020-21

Govt to amend New Drugs and Clinical Trials Rules 2019

CDSCO approves 12 laboratories for BA/BE studies

FAQs on Medical Devices Rules, 2017

FAQs on New Drug, Banned drugs etc.

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner